Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Abstract Introduction This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Methods Eligible patients who had receiv...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rebecca Dent, Geoffrey J. Lindeman, Mark Clemons, Hans Wildiers, Arlene Chan, Nicole McCarthy, Christian F. Singer, Elizabeth Lowe, Claire Watkins, James Carmichael
Médium: Artigo
Jazyk:angličtina
Vydáno: 2013
On-line přístup:https://doi.org/10.1186/bcr3484
https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/bcr3484
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1186/bcr3484
https://breast-cancer-research.biomedcentral.com/counter/pdf/10.1186/bcr3484

Podobné jednotky